Advanced search
Publication Cover
Journal of Neurogenetics Volume 14, 2000 - Issue 2
Submit an article Journal homepage
60
Views
16
CrossRef citations to date
0
Altmetric
Review Article

Advances in Neurofibromatosis 2 (NF2): A Workshop Report

David J. Lim House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USACorrespondence[email protected]
,
Allan E. Rubenstein House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
D. Gareth Evans House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Tyler Jacks House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Bernd G. Seizinger House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Michael E. Baser House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
David Beebe House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Derald E. Brackmann House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
E. Antonio Chiocca House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Richard G. Fehon House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Marco Giovannini House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Robert Glazer House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
James F. Gusella House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
David H. Gutmann House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Bruce Korf House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Frank Lieberman House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Robert Martuza House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Andrea I. McClatchey House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Dilys M. Parry House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Stefan M. Pulst House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Vijaya Ramesh House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
W. Jay Ramsey House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Nancy Ratner House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
J. Lynn Rutkowski House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
,
Martin Ruttledge House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
&
David E. Weinstein House Ear Institute, 2100 West Third Street, Los Angeles, CA, 90027, USA
 show all
Pages 63-106 | Received 19 Feb 1999, Published online: 11 Jul 2009

References

  • Abaza M. M., Makariou E., Armstrong M., Lalwani A. K. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996; 106: 694–699
  • Adamson P. C., Hannah A. L., Blaney S. M., Kitchen B. J., Murphy R. F., Gillespie A. F., Whitcomb P. G., Cropp G. F., Balis F. M. A pediatric phase 1 trial and pharmacokinetic (PK) study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Proc. Amer. Assoc. Cancer Res. 1999; 40: 4776
  • Akagi K., Sandig V., Vooijs M., Van der Valk M., Giovannini M., Strauss M., Berns A. Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Research 1997; 25(9)1766–1773
  • Baser M. E., Ragge N. K., Riccardi V., Janus T., Gantz B., Pulst S. M. Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am. J. Med. Genet. 1996; 64: 563–567
  • Baser M. E., Mautner V., Thakkar S. D., Kluwe L. The natural history of neurofibromatosis 2. Am. J. Hum. Genet. 1998; A63, Suppl. 63 (4 Suppl)
  • Baser M. E., Kluwe L., Mautner V. F. Germ-line NF2 mutations and disease severity in neurofibromatosis type 2 patients with retinal abnormalities. Am. J. Hum. Genet. 1999; 64(4)1230–1233
  • Bianchi A., Mitsunaga S. I., Cheng J. Q., Klein W. M., Jhanwar S. C., Seizinger B., Kley N., Klein-Szanto A. J., Testa J. R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. USA 1995; 92: 10854–10858
  • Birch B., Johnson J. P., Parsa A., Desai R. D., Yoon J. T., Lycette C. A., Li Y. M., Bruce J. N. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. Neurosurgery 1996; 39: 135–140
  • Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376
  • Blessing T., Remy J. S., Behr J. P. Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc. Natl. Acad. Sci. USA 1998; 95: 1427–1431
  • Bobo R. H., Laske D. W., Akbasak A., Morrison P. F., Dedrick R. L., Oldfield E. H. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 1994; 91: 2076–2080
  • Chase M., Chung R. Y., Chiocca E. A. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnology 1998; 16: 444–448
  • Chiocca E. A., Breakefield X. O. Gene therapy for neurological disorders and brain tumors. Humana Press, Totowa, NJ. 1998
  • Defer G. L., Adle-Biassette H., Ricolfi F., Martin L., Authier F. J., Chomienne C., Degos J. D. All trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J. Neurooncol. 1997; 34(2)169–177
  • Deguen B., Merel P., Goutebroze L., Giovannini M., Reggio H., Arpin M., Thomas G. Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum. Mol. Genet. 1998; 7: 217–226
  • Den Bakker M. A., Riegman P. H., Hekman R. A., Boersma W., Janssen P. J., Van der Kwast T. H., Zwarthoff E. C. The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene 1995; 10: 757–763
  • Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris A. E. A clinical study of type 2 neurofibromatosis. Q. J. Med. 1992; 84: 603–618
  • Evans D. G.R., Mason S., Huson S. M., Ponder M., Harding A. E., Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study. J. Neurol. Neurosurg. Psychiat. 1997; 62: 361–366
  • Evans D. G.R., Trueman L., Wallace A., Collins S., Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): Evidence for more severe disease associated with truncating mutations. J. Med. Genet. 1998; 35: 450–455
  • Fehon R. G., Oren T., LaJeunesse D. R., Melby T. E., McCartney B. M. Isolation of mutations in the Drosophila homologues of the human neurofibromatosis 2 and yeast CDC42 genes using a simple and efficient reverse-genetic method. Genetics 1997; 146: 245–252
  • Fong T. A., Shawver L. K., Sun L., Tang C., App H., Powell T. J., Kim Y. H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K. P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999; 59(1)99–106
  • Fraefel C., Song S., Lim F., Lang P., Yu L., Wang Y., Wild P., Geller A. I. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 1996; 70: 7190–7197
  • Furth P. A., St., Onge L., Boger H., Gruss P., Gossen M., Kistner A., Bujard H., Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 1994; 91(20)9302–9306
  • Giovannini M., Robanus-Maandag E., Niwa-Kawakita M., Van der Valk M., Woodruff J., Goutebroze L., Merel P., Berns A., Thomas G. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 1999; 13: 978–986
  • Gonzalez-Agosti C., Xu L., Pinney D., Beauchamp R., Hobbs W., Gusella J., Ramesh V. The Merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 1996; 13: 1239–1247
  • Gusella J., Ramesh V., MacCollin M., Jacoby L. B. Neurofibromatosis 2: Loss of Merlin's protective spell. Current Opinion in Genetics and Development 1996; 6: 87–92
  • Gutmann D. H., Aylsworth A., Carey J. C., Korf B., Marks J., Pyeritz R. E., Rubenstein A., Viskochil D. The diagnostic evaluation and multi-disciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J. Am. Med. Assoc. 1997; 278: 51–7
  • Gutmann D. H., Geist R. T., Xu H. M., Kim J. S., Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum. Molec. Genet. 1998; 7: 335–345
  • Harris S. R., Thorgeirsson U. P. Tumor angiogenesis: Biology and therapeutic prospects. In Vivo 1998; 12: 563–570
  • Howard M., Rizzell R. A., Bedwell D. M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine 1996; 2: 467–469
  • Huynh D. P., Pulst S. M. Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. Oncogene 1996; 13: 73–84
  • Huynh D. P., Mautner V., Baser M. E., Stavrou D., Pulst S. M. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J. Neuropath. Exp. Neurol. 1997; 56: 382–390
  • Jacoby L. B., MacCollin M., Barone R., Ramesh V., Gusella J. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosome Cancer 1996; 17: 45–55
  • Jacoby L. B., Jones D., Davis K., Kronn D., Short M. P., Gusella J., MacCollin M. Molecular analysis of the NF2 tumor suppressor in schwannomatosis. Am. J. Hum. Genet. 1997; 61(6)1293–1302
  • Jooss K., Yang Y., Wilson J. M. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Therapy 1996; 7: 1555–1566
  • Kanter W. R., Eldridge R., Fabricant R., Allen J. C., Koerber T. Central neurofibromatosis with bilateral acoustic neuroma, genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 1980; 30: 851–859
  • Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Funsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum. Genet. 1996; 98: 534–538
  • Koltover I., Salditt T., Radler J. O., Safinya C. R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 1998; 281: 78–81
  • Kuhn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995; 269: 1427–1429
  • Kyritsis A. P. Chemotherapy for meningiomas. J. Neurooncol. 1996; 29: 269–272
  • LaJeunesse D. R., McCartney B. M., Fehon R. G. Structural analysis of Drosophila Merlin reveal functional domains important for growth control and subcellular localization. J. Cell Biol. 1998; 141(7)1589–1599
  • MacCollin M., NF2 germline mutation map, initially compiled June, 1995, revised November, 1996 accessed on the World Wide Web at http://neuro-www.mgh.harvard.edu/neurowebforum/NeurofibromatosisMenu.html. References for the map, including unpublished sources of information, are listed at the map site
  • MacCollin M., Woodfin W., Kronn D., Short M. P. Schwannomatosis: A clinical and pathological study. Neurology 1996; 46: 1072–1079
  • Mautner V. F., Tatagiba M., Lindenau M., Funsterer C., Pulst S. M., Baser M. E., Kluwe L., Zanella F. E. Spinal tumors in patients with neurofibromatosis 2: MR imaging study of frequency, multiplicity, and variety. AJR Am. J. Roentgenol. 1995; 165: 951–955
  • Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38: 880–885
  • Mautner V. F., Lindenau M., Baser M. E., Kluwe L., Gottschalk J. Skin abnormalities in neurofibromatosis 2. Arch. Dermatol. 1997; 133: 1539–1543
  • McCartney B. M., Fehon R. G. Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J. Cell Biol. 1996; 133: 843–852
  • McClatchey A. I., Saotome I., Ramesh V., Gusella J. F., Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997; 11: 1253–1265
  • McClatchey A. I., Saotome I., Mercer K., Crowley D., Gusella J. F., Bronson R. T., Jacks T. Mice heterozygous for a mutation at the NF2 turnor suppressor locus develop a range of highly metastic tumors. Genes Dev. 1998; 12: 1121–1133
  • Messing A., Behringer R. R., Wrabetz L., Hammang J. P., Lemke G., Palmiter R. D., Brinster R. L. Hypomyelinating peripheral neuropathies and schwannomas in transgenic mice express inf SV40 T-antigen. J. Neurosci. 1994; 14: 3533–3539
  • Miklos G. L.G., Rubin G. M. The role of the genome project in determining gene function: Insights from model organisms. Cell 1996; 86: 521–529
  • Miller N., Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Human Gene Therapy 1997; 8: 803–815
  • Minchinton A. I., Fryer K. H., Wendt K. R., Clow K. A., Hayes M. M. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996; 7(3)339–343
  • Monia B. P., Johnston J. F., Sasmor H., Cummins L. L. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem. 1996; 271: 14533–14540
  • Mukhopadhyay T., Roth J. A. Antisense regulation of oncogenes in human cancer. Critical Reviews in Oncogenesis 1996; 7: 151–190
  • Murthy A., Gonzalez-Agosti C., Cordero E., Pinney D., Candia C., Solomon F., Gusella J., Ramesh V. NHE-RF, a regulatory cofactor for Na(+)-H(+) exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem. 1998; 273: 1273–1276
  • Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F. H., Verma I. M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263–267
  • Neurofibromatosis Conference Statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 1988; 45: 575–578
  • Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am. J. Med. Genet. 1994; 52: 450–491
  • Parry D. M., MacCollin M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M. D., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am. J. Hum. Genet. 1996; 59: 529–539
  • Paulus W., Baur I., Boyce F. M., Breakefield O. X., Reeves S. A. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virology 1996; 70: 62–67
  • Pelton P. D., Sherman L. S., Rizvi T. A., Marchionni M. A., Wood P., Friedman R. A., Ratner N. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998; 17(7)2195–2209
  • Phuphanich S., Scott C., Fischbach A. J., Langer C., Yung W. K. All-trans retinoic acid: A phase II Radiation Therapy Oncology Group study (RTOG 91–13) in patients with recurrent malignant astrocytoma. J. Neurooncol. 1997; 34(2)193–200
  • Pulst S. M., Rouleau G. A., Fain P., Sieb J. P. Familial meningioma is not allelic to NF2. Neurology 1993; 43: 2096–2098
  • Rainov N. G., Zimmer C., Chase M., Kramm C. M., Chiocca E. A., Weissleder R., Breakefield X. O. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Therapy 1995; 6: 1543–1552
  • Reczek D., Berryman M., Bretscher A. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol. 1997; 139: 169–179
  • Rivera V. M., Clackson T., Natesan S., Pollock R., Amara J. F., Keenan T., Magari S. R., Phillips T., Courage N. L., Cerasoli F., Jr., Holt D. A., Gilman M. A humanized system for pharmacological control of gene expression. Nature Medicine 1996; 2: 1028–1032
  • Rizvi N. A., Marshall J. C., Ness E., Yoe J., Gill G. M., Truglia J. A., Loewen G. R., Jaunakais D., Ulm E. H., Hawkins M. J. Phase 1 study of 9-cis-retinoic acid (ALRT 1057 capsules) in adults with advanced cancer. Clin. Cancer Res. 1998; 4: 1427–1442
  • Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane organizing protein causes neurofibromatosis type 2. Nature 1993; 363: 515–521
  • Rouleau G., Seizinger B. R., Ozelius L. G. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987; 329: 246–248
  • Russell D. W., Hirata R. K. Human gene targeting by viral vectors. Nature Genetics 1998; 18: 325–330
  • Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D., Michels V., Riccardi V. M., Weksberg R., Kitamura K., Bradburn J. M., Hall B. D., Propping P., Rouleau G. A. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am. J. Hum. Genet. 1996; 59: 331–342
  • Sainz J., Huynh D. P., Figueroa K., Ragge N. K., Baser M. E., Pulst S. M. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum. Mol. Genet. 1994; 6: 885–891
  • Samid D., Hudgins W. R., Shack S., Liu L., Prasanna P., Myers C. E. Phenylacetate and phenylbutyrate as novel differentiation inducers. Adv. Exp. Med. Biol. 1997; 400A: 501–505
  • Scherer S. S., Gutmann D. H. Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J. Neurosci. Res. 1996; 46: 595–605
  • Schiedner G., Morral N., Parks R. J., Wu Y., Koopmans S. C., Langston C., Graham F. L., Beaudet A. L., Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genetics 1998; 18: 180–183
  • Schrell U. M., Rittig M. G., Koch U. H., Marschalek R., Anders M., Kiesewetter F., Fahlbusch R. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 1997; 86(5)840–844
  • Scoles D. R., Huynh D. P., Morcos P. A., Coulsell E. R., Robinson N. G., Tamanoi F., Pulst S. M. Neurofibromatosis 2 tumour suppressor schwannomin interacts with beta II-spectrin. Nature Genetics 1998; 18: 354–359
  • Seizinger B. R., Martuza R. L., Gusella J. F. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986; 322: 644–647
  • Sekido Y., Pass H. I., Bader S., Mew D. J., Christman M. F., Gazdar A. F., Minna J. D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995; 55: 1227–1231
  • Shannah S. M., Alberta J. A., Giannobile W. V., Guha A., Kwon Y. K., Carroll R. S., Black P. M., Stiles C. D. Detection of platelet-derived growth factor receptors on human meningiomas. Cancer Res. 1997; 57: 4141–4147
  • Shawver L. K., Schwartz D. P., Mann E., Chen H., Tsai J., Chu L., Longhi M., Meredith S., Germain L., Jacobs J. S., Tang C., Ullrich A., Berens M. E., Hersh E., McMahon G., Hirth K. P., Powell T. J. Inhibition of platelet derived growth factor mediated signal transduction and tunor growth by N-[4-(trifluoromethyl)-phenyl] 5-methylisoxazole-4-carboxamide. Clin. Cancer Res. 1997; 3: 1167–1177
  • Sherman L., Xu H. M., Geist R. T., Saporito-Irwin S., Howells N., Ponta H., Herrlich P., Gutmann D. H. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997; 15: 2505–2509
  • Stangl A. P., Wellenreuther R., Lenartz D., Kraus J. A., Menon A. G., Schramm J., Wiestler O. D., Von Deimling A. Clonality of multiple meningiomas. J. Neurosurg. 1997; 86: 853–858
  • Stemmer-Rachamimov A. O., Gonzalez-Agosti C., Xu L., Burwick J. A., Beauchamp R., Pinney D., Louis D. N., Ramesh V. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J. Neuropath. Exper. Neuro. 1997; 56: 735–742
  • Todo T., Adams E. F., Fahlbusch R., Dingermann T., Werner H. Autocrine growth stimulation of human meningioma cells by platelet derived growth factor. J. Neurosurg. 1996; 84: 852–858
  • Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis tumor suppressor. Cell 1993; 72: 791–800
  • Tsukita S., Yonemura S., Tsukita S. ERM proteins: Head-to-tail regulation of actin—plasma membrane interaction. Trends Biochem. Sci. 1997; 22: 53–58
  • Wang S., Vos J. M. A hybrid herpes virus infectious vector based on Epstein-Barr virus and Herpes Simplex Virus Type 1 for gene transfer into human cells in vitro and. in vivo. J. Virol 1996; 70: 8422–8430
  • Wang Y., Krushel L. A., Edelman G. M. Targeted DNA recombination in vivo using an adenovirus carrying the ere recombinase gene. Proc. Natl. Acad. Sci. USA 1996; 93: 3932–3936
  • Weinstein D. E., Burrola P. G., Lemke G. Premature Schwann cell differentiation and hypermyelination in mice expressing a targeted antagonist of the POU transcription factor SCIP. Molecular and Cellular Neurosciences 1995; 6(3)212–229
  • Wellenreuther R., Kraus J. A., Lenartz D., Menon A., Schramm J., Louis D. N., Ramesh V., Gusella J. F., Wiestler O. D., Von Deimling A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am. J. Pathol. 1995; 146: 827–832
  • Yung W. K., Kyritsis A. P., Gleason M. J., Levin V. A. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res. 1996; 2: 1931–1935
  • Zorick T. S., Lemke G. Schwann cell differentiation. Curr. Opin. Cell Biol. 1996; 8: 870–876

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.